Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer.
about
Overlay of conventional angiographic and en-face OCT images enhances their interpretation.Indium-111 capromab pendetide in the management of recurrent prostate cancerImaging on nodal staging of prostate cancer.Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.Technological development and advances in single-photon emission computed tomography/computed tomography.Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CTActivity estimation in radioimmunotherapy using magnetic nanoparticles.Combined SPECT and Multidetector CT for Prostate Cancer Evaluations.Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy.Technology insight: monoclonal antibody imaging of prostate cancer.Imaging techniques for prostate cancer: implications for focal therapyPositron emission tomography and molecular imaging of the prostate: an update.Imaging localized prostate cancer: current approaches and new developments.The roles of PET and PET/CT in the diagnosis and management of prostate cancer.New horizons in prostate cancer imaging.Salvage HIFU for recurrent prostate cancer after radiotherapy.Acquisition parameters for oncologic imaging with a new SPECT/multislice CT scanner.Prospects in radionuclide imaging of prostate cancer.Prostate-specific membrane antigen-based imaging.Individualized image-based lymph node irradiation for prostate cancer.Molecular imaging agents for SPECT (and SPECT/CT).Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer.Progress in SPECT/CT imaging of prostate cancer.Simple, mild, one-step labelling of proteins with gallium-68 using a tris(hydroxypyridinone) bifunctional chelator: a 68Ga-THP-scFv targeting the prostate-specific membrane antigen.Functional and Targeted Lymph Node Imaging in Prostate Cancer: Current Status and Future Challenges.
P2860
Q24814369-D2D2757D-598D-46F0-8D8E-F3D9D9490995Q28268862-26744295-B76A-428A-9E35-54ABFF870F96Q30244033-63A409E3-EBA4-4E0C-B731-32C192C7159FQ34139498-FA01C3A7-D58F-49A4-830E-14EC97574535Q34626322-E7618321-CEBA-4E62-9540-7F968C06C09EQ34995973-1B4EB9F5-BACF-4805-87C5-7FDCA1E17B03Q35538763-2F0D869A-4F40-4E96-8D14-6EC059CD1288Q35679253-4AA0EC07-070D-4995-A5A0-5FCFB75C887BQ36010923-8EBC027E-6C77-4F8B-9B8E-B07912A4BDD5Q36445286-03589201-9693-415E-979F-B65D97226FB2Q36460818-B61009D3-3190-470A-819E-B7A373F83D88Q36462108-4462EABD-6F78-4793-B761-8C5492FD4B40Q36469177-14C37648-B317-4B34-9AE8-A88F6D9B8818Q37050873-355EB47B-3CDD-44F6-A2B6-49A0BC7A053BQ37242030-FACD24F1-349E-48D7-B334-46D1CC0E6FB5Q37293116-956A2DE2-79F9-4C16-AC80-6CEBF9E97B79Q37668118-5232DD01-5FF1-4C44-B24D-1D588BFA578BQ37962869-5B227B40-1831-461C-BFFA-1214358D480CQ38015617-9D91FC6F-B358-42C6-BCE6-7B69F44A5E5BQ38109812-DBFF47A1-753F-47EB-B6A1-627B76E480C0Q38169570-A3E6A8D0-0428-4CA2-8FD3-8A92B4726126Q39433661-0268A229-146C-44D7-A2EC-C2675D09F818Q46044144-59EEA881-0752-46AF-87BE-74CAF04A8CD2Q47105948-42C6893C-9540-4382-A24D-14A242D4821FQ47829959-E3A60ABF-A75F-45BE-A70F-F1169AD924A8
P2860
Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer.
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Impact of fusion of indium-111 ...... ith recurrent prostate cancer.
@ast
Impact of fusion of indium-111 ...... ith recurrent prostate cancer.
@en
type
label
Impact of fusion of indium-111 ...... ith recurrent prostate cancer.
@ast
Impact of fusion of indium-111 ...... ith recurrent prostate cancer.
@en
prefLabel
Impact of fusion of indium-111 ...... ith recurrent prostate cancer.
@ast
Impact of fusion of indium-111 ...... ith recurrent prostate cancer.
@en
P2093
P1476
Impact of fusion of indium-111 ...... ith recurrent prostate cancer.
@en
P2093
Chris J Schettino
Elissa L Kramer
Herbert Lepor
Marilyn E Noz
Priya Padmanabhan
Samir Taneja
P304
P356
10.2214/AJR.183.2.1830519
P407
P577
2004-08-01T00:00:00Z